Precigen (PGEN) Cash & Equivalents (2012 - 2026)

Precigen (PGEN) has 15 years of Cash & Equivalents data on file, last reported at $7.5 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 23.47% year-over-year to $7.5 million in Q1 2026; TTM through Mar 2026 was $7.5 million, a 23.47% increase from a year earlier, with the FY2025 full-year figure at $30.2 million, up 2.43% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $7.5 million, down from $30.2 million in the prior quarter.
• Over the last five years, Cash & Equivalents for PGEN reached as high as $43.8 million in Q2 2022 and fell as low as $4.9 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $17.3 million across 5 years, with a median of $13.8 million in 2025.
• Across the five-year window, Cash & Equivalents sank 78.27% in 2022 and soared 289.51% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $4.9 million in 2022, then surged by 55.99% to $7.6 million in 2023, then surged by 289.51% to $29.5 million in 2024, then gained by 2.43% to $30.2 million in 2025, then sank by 75.26% to $7.5 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $7.5 million in Q1 2026, $30.2 million in Q4 2025, and $14.3 million in Q3 2025.